The cost–benefit of screening is proven, and the cost-effectiveness increases with increasing effectiveness of therapies, such as SGLT2 inhibitors, therefore thorough clinical investigation is recommended when HF is suspected. This evidence concerns the gene SLC5A2 and hydrops fetalis.